Prise en compte de l’hétérogénéité inter-centres et du biais de non-comparabilité avec un modèle à fragilité pour estimer la mortalité en excès dans les essais cliniques multicentriques
Juste Goungounga(Centre National de la Recherche Scientifique), Roch Giorgi(Inserm), Nathalie Grafféo(Inserm), Hadrien Charvat(Juntendo University)
Cited by 0
Related Papers
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
|The Lancet Oncology|2021|684
Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality in a Japanese Cohort
|JAMA Internal Medicine|2019|204
Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study
|The Lancet Regional Health - Europe|2022|155
Impact of population aging on trends in diabetes prevalence: A meta‐regression analysis of 160,000 Japanese adults
|Journal of Diabetes Investigation|2015|138
Diabetes mellitus and cancer risk: Pooled analysis of eight cohort studies in Japan
|Cancer Science|2013|108